Compuchem

Compugen is a clinical-stage therapeutic discovery and development company that utilizes a proprietary computational platform to identify novel drug targets and develop first-in-class therapeutics. The company primarily focuses on immuno-oncology, targeting novel checkpoints to overcome resistance to existing cancer treatments. Its lead programs include COM701, a first-in-class antibody targeting PVRIG, and COM902, an antibody targeting TIGIT. Compugen has established significant partnerships with major pharmaceutical companies like Bristol Myers Squibb and Gilead Sciences to advance its pipeline. The company's approach integrates data science with experimental biology to accelerate the discovery of new biological pathways.